Blue Ridge Capital’s Arbutus Biopharma ABUS Stock Holding History

Blue Ridge Capital’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-1,700,000	Closed	-$20.2M	–	49
2015 Q2	$20.2M	Hold	1,700,000	–	–	0.23%	46
2015 Q1	$29.7M	Buy	+1,700,000	New	+$34.8M	0.34%	43

Other funds holding ABUS

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Blue Ridge Capital's ABUS Position: Q3 2015 in Review

Blue Ridge Capital sold out of Arbutus Biopharma (ABUS) in Q3 2015, closing a stake of 1,700,000 shares — an estimated $20.2M sold.

Blue Ridge Capital first reported a position in ABUS in Q1 2015 and held it in 2 quarters. The position peaked at $29.7M in Q1 2015. 55 funds tracked by Wall St. Rank hold ABUS as of Q3 2015.

Blue Ridge Capital reported no remaining Arbutus Biopharma position as of Q3 2015 after selling out during the quarter.
Blue Ridge Capital sold 1,700,000 Arbutus Biopharma shares in Q3 2015, an estimated $20.2M.
Blue Ridge Capital first reported a position in Arbutus Biopharma in Q1 2015 and held it in 2 quarters.
Blue Ridge Capital's Arbutus Biopharma position peaked at $29.7M in Q1 2015.
55 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2015.

Based on Blue Ridge Capital's 13F filing for Q3 2015, filed 16 Nov 2015.